<div id="readability-page-1"><p>AQR Capital Management LLC boosted its holdings in  Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 10.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,606,079 shares of the biotechnology company's stock after purchasing an additional 712,190 shares during the quarter. AQR Capital Management LLC owned about 2.83% of Exelixis worth $335,238,000 at the end of the most recent quarter.</p><ul><li>3 Stocks to Buy for a Soft Landing, If There Is One</li></ul><p>A number of other institutional investors have also recently made changes to their positions in EXEL. Belpointe Asset Management LLC purchased a new position in  Exelixis in the 1st quarter worth about $572,000.  Fox Run Management L.L.C. purchased a new position in shares of  Exelixis in the second quarter worth approximately $321,000.  D.A. Davidson &amp; CO. bought a new stake in  Exelixis during the second quarter valued at approximately $212,000.  Fortis Capital Advisors LLC purchased a new stake in  Exelixis during the first quarter valued at approximately $572,000.  Finally, Capital Fund Management S.A. raised its position in  Exelixis by 6.6% in the second quarter. Capital Fund Management S.A. now owns 283,639 shares of the biotechnology company's stock worth $12,501,000 after acquiring an additional 17,673 shares during the period. Hedge funds and other institutional investors own  85.27% of the company's stock. </p><h2>Exelixis Stock Performance</h2><p>NASDAQ EXEL opened at $40.88 on Friday. The company has a market capitalization of $10.96 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 0.75 and a beta of 0.40. The company's 50-day simple moving average is $40.77 and its two-hundred day simple moving average is $40.83. Exelixis, Inc. has a one year low of $31.90 and a one year high of $49.62. </p><ul><li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li></ul><p>Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million for the quarter, compared to analyst estimates of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The firm's quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.47 earnings per share.  Equities analysts expect that  Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year. </p><h2>Insider Transactions at Exelixis</h2><p>In other Exelixis news, EVP Dana Aftab sold 48,383 shares of Exelixis stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the completion of the sale, the executive vice president owned 664,778 shares of the company's stock, valued at approximately $28,253,065. The trade was a 6.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mary C. Beckerle sold 24,622 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the transaction, the director owned 21,380 shares in the company, valued at approximately $896,463.40. This trade represents a 53.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 245,235 shares of company stock worth $10,490,600. Insiders own  2.82% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>7 Best Cancer Stocks to Invest in Now</li></ul><p>Several research analysts have recently commented on the company. Cowen  reaffirmed a &#34;buy&#34; rating on shares of Exelixis in a research note on Wednesday, November 5th. UBS Group increased their price objective on shares of Exelixis from $35.00 to $40.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, November 6th. The Goldman Sachs Group initiated coverage on shares of Exelixis in a report on Wednesday, September 17th. They issued a &#34;buy&#34; rating and a $47.00 target price on the stock. Royal Bank Of Canada  reaffirmed a &#34;sector perform&#34; rating and set a $45.00 target price on shares of Exelixis in a research note on Tuesday, October 21st. Finally, Leerink Partners raised shares of Exelixis from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $48.00 price target on the stock in a research note on Tuesday, October 21st. One research analyst  has rated the stock with a Strong Buy rating, fifteen have issued  a Buy rating and twelve have issued  a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $45.45.</p><p><b>Get Our Latest Stock Report on Exelixis</b></p><h2>Exelixis Profile</h2> (Free Report)<p>Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Exelixis</li><li>3 Small Caps With Big Return Potential</li><li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li><li>Stock Sentiment Analysis: How it Works</li><li>The Best Holiday Present You Can Give Yourself? Costco Stock</li><li>How to Calculate Inflation Rate</li><li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li></ul><p><strong>Want to see what other hedge funds are holding EXEL?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Exelixis Right Now?</h2><p>Before you consider Exelixis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p><p>While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EXEL

<p>AQR Capital Management LLC increased its stake in Exelixis, Inc. by 10.3% in Q2, owning 2.83% of the company. Exelixis reported strong Q2 earnings, beating estimates. Analysts have mixed ratings, with price targets between $35 and $48.</p>

AQR Capital Management LLC Purchases 712,190 Shares of Exelixis, Inc. $EXEL